IV. Перелік літературних джерел, використаних при розробці клінічного протоколу медичної допомоги
1. World Health Organization (WHO) Off-label use of medicines for COVID-19, 31.03.2020. https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19
2. World Health Organization (WHO). Clinical management of COVID-19, 27.05.2020. https://www.who.int/publications-detail/clinical-management-of-covid-19
3. World Health Organization (WHO). Living guidance "Corticosteroids for COVID-19", 02.09.2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1
4. Всесвітня організація охорони здоров'я (ВООЗ). Клінічна допомога при важкій гострій респіраторній інфекції: інструментарій. Адаптовано до COVID-19. https://apps.who.int/iris/bitstream/handle/10665/333001/WHO-2019-nCoV-SARI- toolkit-2020.1-ukr.pdf?sequence=1&isAllowed=y
5. European Medicines Agency (EMA) COVID-19: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes, 01.04.2020. https://www.ema.europa.eu/en/news/covid-19-chloroquine-hydroxychloroquine-only-be- used-clinical-trials-emergency-use-programmes
6. European Medicines Agency (EMA) provides recommendations on compassionate use of remdesivir for COVID-19, 03.04.2020. https://www.ema.europa.eu/en/news/ema-provides-recommendations-compassionate-use- remdesivir-covid-19
7. European Medicines Agency (EMA) Summary on compassionate use Remdesivir, 03.04.2020. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf
8. EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation, 11.05.2020. https://www.ema.europa.eu/en/news/ema-recommends-expanding-remdesivir- compassionate-use-patients-not-mechanical-ventilation
9. European Medicines Agency (EMA). First COVID-19 treatment Remdesivir recommended for EU authorisation, 25.06.2020. https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
10. European Medicines Agency (EMA). Summary of product characteristics of Veklury (remdesivir) https://www.ema.europa.eu/en/medicines/human/EPAR/veklury
11. European Medicines Agency (EMA) EU authorities agree new measures to support availability of medicines used in the COVID-19 pandemic, 06.04.2020: https://www.ema.europa.eu/en/news/eu-authorities-agree-new-measures-support- availability-medicines-used-covid-19-pandemic
12. European Medicines Agency (EMA) Compassionate use https://www.ema.europa.eu/en/human-regulatory/research-development/compassionate- use
13. U.S. Food and Drug Administration (FDA). FDA issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease, 01.05.2020. https://www.fda.gov/media/137564/download
14. U.S. Food and Drug Administration (FDA). Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734™) https://www.fda.gov/media/137566/download
15. U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of chloroquine phosphate and hydroxychloroquine sulfate for treatment of COVID-19, 28.03.2020. https://www.fda.gov/media/136534/download
16. U.S. Food and Drug Administration (FDA). FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine, 15.06.2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use- authorization-chloroquine-and
17. U.S. Food and Drug Administration (FDA) Expanded Access. https://www.fda.gov/news-events/public-health-focus/expanded-access
18. U.S. Food and Drug Administration (FDA). FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of a COVID-19 Treatment Authorized for Emergency Use (co-administration of remdesivir and chloroquine phosphate or hydroxychloroquine sulfate is not recommended), 15.06.2020 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-
fda-warns-newly-discovered-potential-drug-interaction-may-reduce
19. Interim clinical guidance for adults with suspected or confirmed COVID- 19 in Belgium https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19 InterimGuidelines Treatment ENG.pdf
20. Recommandations pour le traitement des enfants atteints de COVID-19 Belgian Pediatric Covid-19 Task Force (Adaptation du protocole original de la KULeuven http://gbs-vbs.org/fileadmin/user_upload/Unions/PED/Belg_Recomm_COVID_ped_31mar_FR.pdf
21. French legal order. Decree No. 2020-314 of March 25, 2020 supplementing Decree No. 2020-293 of March 23, 2020 prescribing the general measures necessary to deal with the COVID-19 epidemic in the context of the state of health emergency. https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000041755775&cat egorieLien=id
22. World Health Organization (WHO). Targeted Update: Safety and efficacy of hydroxychloroquine or chloroquine for treatment of COVID-19, 17.06.2020 https://www.who.int/publications/m/item/targeted-update-safety-and-efficacy-of-
hydroxychloroquine-or-chloroquine-for-treatment-of-covid-19
23. World Health Organization (WHO). Hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment was being stopped, 17.06.2020: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-
novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
24. Centers for Disease Control and Prevention (CDC) Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management- patients.html
25. CDC Information for Clinicians on Therapeutic Options for COVID-19 Patients. https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html
26. U.S. National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines;sEP;https://www.covid19treatmentguidelines.nih.gov/whats-new/
27. Infectious Diseases Society of America. Guidelines on the Treatment and Management of Patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management
28. Austrian Society for Internistic and General Intensive Care Medicine and Emergency Medicine, OGARI). ICU Therapy guideline for the treatment of patients with a SARS CoV2 infection. https://www.anaesthesie.news/wp-content/uploads/%C3%96GARI-FASIM-%C3%96GIAIN-Guideline-NEU-Covid19-290320.pdf
29. China National Health Commission. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). https://www.chinadaily.com.cn/pdf/2020/1.Clinical.Protocols.for.the.Diagnosis.and.Treat ment.of.COVID-19.V7.pdf
30. Chinese Centre for Disease Control and Prevention. Diagnosis and treatment. COVID-19 Prevention and Control. http://www.chinacdc.cn/en/COVID19/202002/P020200310326343385431.pdf
31. Circolare del ministero con raccomandazioni per persone immunodepresse: Raccomandazioni per la gestione dei pazienti immunodepressi residenti nel nostro Paese in corso di emergenza da COVID-19. http://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=73753&parte=1%0&serie=null
32. Lietuvos Respublikos sveikatos apsaugos ministro 2020 m. kovo 17 d. sakymu Nr. V383: SUAUGUSIJ COVID-19 LIGOS (KORONAVIRUSO INFEKCIJOS) DIAGNOSTIKOS IR GYDYMO TVARKOS APRAAS) http://sam.lrv.lt/uploads/sam/documents/files/COVID-19 dgn%20ir%20gydymo%20aprasas%20SUVESTINIS.pdf

33. Protocole pour la prise en charge de Patients ayant une infection COVID-19 confirme ou suspectde, CONSEIL SUPERIEUR DES MALADIES INFECTIEUSES https://sante.public.lu/fr/espace-professionnel/recommandations/direction-sante/000- covid-19/index.html
34. De Stichting Werkgroep Antibiotica Beleid (SWAB). Medicamenteuze behandelopties bij patienten met COVID-19 (infecties met SARS-CoV-2), De Stichting Werkgroep Antibiotica Beleid https://swab.nl/nl/covid-19
35. Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS). Tratamientos disponibles para el manejo de la infeccion respiratoria por SARS-CoV-2 https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%E2%80%9119/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/
36. National Public Health Organization (NPHO), Ministry of Health of Greece.      SARS-CoV-2. https://eody.gov.gr/wp-content/uploads/2020/03/covid-19-odigies-therapeias.pdf
37. The First Affiliated Hospital, Zhejiang University School of Medicine. Handbook of COVID-19 Prevention and Treatment, 2020: https://covid-19.alibabacloud.com/
38. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). https://www.esicm.org/wp-content/uploads/2020/03/SSC-COVID19-GUIDELINES.pdf
39. Ministry of Health, labour and Welfare of Japan. Clinical Management of Patients with COVID-19. A guide for front-line healthcare workers (Version 2.1). https://www.mhlw.go.jp/content/000646531.pdf
40. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of Lopinavir-ritonavir in adults hospitalized with severe Covid-19. № Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001282. https://www.nejm.org/doi/full/10.1056/NEJMoa2001282
41. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. № Engl J Med. (2020). doi: 10.1056/NEJMoa2015301. https://www.nejm.org/doi/full/10.1056/NEJMoa2015301?query=featured_coronavirus
42. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (2020); 395:1569 - 1578.
doi: 10.1016/S0140-6736(20)31022-9 https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)31022-9.pdf
43. J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, et al. Remdesivir for the treatment of covid-19-preliminary report. № Engl J Med (2020) https://doi.org/10.1056/netjmoa2007764 https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?source=nejmfacebook&mediu m=organic-social&fbclid=IwAR1nvgVskaoitXDSLCA6YfMC-bhn80A5XtLQyo0HCaJhxlEdld1Nd6opDK0#article citing articles
44. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir, 29.06.2020 https://www.recoverytrial.net/files/lopinavir-ritonavir-recovery-statement- 29062020 final.pdf
45. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5.06.2020 https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf
46. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext?fbclid=IwAR0unXed9JIjtou-tTSC8iM3NBoXQRYdslK34VZZgiuNxmKE3FSc3Fo9z5A#section-3d6acba1-acea-4be2-8dc9-b7e14e5b6583
47. Cai, Q. et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering. https://doi.org/10.10167j.eng.2020.03.007 https://www.sciencedirect.com/science/article/pii/S2095809920300631
48. Yohei D et al. Preliminary Report of the Favipiravir Observational Study in Japan http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19 casereport en 20052 9.pdf
49. Uno studio randomizzato multicentrico in aperto per valutare l'efficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19, 17.06.2020 https://www.aifa.gov.it/documents/20142/1123276/studio_RE_Toci17.06.2020.pdf/c32ed144-ce26-d673-6e4d-11d5d0d84836
50. American Society of Health-System Pharmacists (ASFP). Assessment of Evidence for COVID-19-Related Treatments https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Coronavirus/docs/ASHP-COVID-19-Evidence-Table.ashx
51. Interactions with Experimental COVID-19 Therapies https://www.covid19-druginteractions.org/
52. Belgian Society on Thrombosis and Haemostasis (BSTH). Anticoagulation management in COVID-19 positive patients BSTH consensus guideline https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19Anticoagulation Management.pdf
53. Brigham and Women's Hospital COVID-19 Clinical Guidelines. Thrombotic Disease. https://covidprotocols.org/protocols/hematology/#thrombotic-disease
54. COVID-19 anticoagulation recommendations in children, 18.06.2020 https://onlinelibrary.wiley.com/doi/10.1002/pbc.28485
55. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum, 21.05.2020 https://link.springer.com/article/10.1007/s11239-020-02138-z
56. Groupe d'intdret en Hdmostase Pdriopdratoire (GIHP) and the Groupe Frangais d'dtudes sur I'Hdmostase et la Thrombose (GFHT). Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring, 19.06.2020 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303590/
57. Rawson T. et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing, 02.05.2020 https://pubmed.ncbi.nlm.nih.gov/32358954/
58. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital, 01.05.2020 https://www.nice.org.uk/guidance/ng173
59. British Paediatric Society. Guidance for the clinical management of children admitted to hospital with suspected COVID-19 https://www.rcpch.ac.uk/sites/default/files/2020-03/bprs management of children admitted to hospital with covid19-20200319.pdf
60. Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review, 08.05.2020 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290645/
61. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America https://academic.oup.com/cid/article/53/7/e25/424286#74161858
62. The acute management of paediatric coronavirus disease 2019 (COVID-19), 20.04.2020 https://www.cps.ca/en/documents/position/the-acute-management-of-paediatric-coronavirus-disease-2019covid-19
63. Coronavirus disease 2019 (COVID-19): Management in children, 14.09.2020 https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-management-in-children